LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study

Vasseur, Loïc; Fenwarth, Laurène; Lambert, Jérôme; Botton, Stéphane de; Figeac, Martin; Villenet, Céline; Heiblig, Maël; Dumas, Pierre‐Yves; Récher, Christian; Berthon, Céline; Lemasle, Émilie; Lebon, Delphine; Lambert, Juliette; Terré, Christine; Celli-Lebras, Karine; Dombret, Hervé; Preudhomme, Claude; Cheok, Meyling; Itzykson, Raphaël; Duployez, Nicolas

doi:10.1182/bloodadvances.2023010155

Cited by 4 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, several signatures and scores have been proposed [ 178 , 179 , 180 ]. Among them, LSC17, a 17-gene stemness score, was associated with poor clinical outcomes in multiple AML cohorts, even in the context of ELN 2017 classification [ 181 , 182 , 183 , 184 ].…”

Section: Emerging Biological Risk Factorsmentioning

confidence: 99%

Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors

Boscaro¹,

Urbino²,

Catania³

et al. 2023

Cancers

View full text Add to dashboard Cite

An accurate estimation of AML prognosis is complex since it depends on patient-related factors, AML manifestations at diagnosis, and disease genetics. Furthermore, the depth of response, evaluated using the level of MRD, has been established as a strong prognostic factor in several AML subgroups. In recent years, this rapidly evolving field has made the prognostic evaluation of AML more challenging. Traditional prognostic factors, established in cohorts of patients treated with standard intensive chemotherapy, are becoming less accurate as new effective therapies are emerging. The widespread availability of next-generation sequencing platforms has improved our knowledge of AML biology and, consequently, the recent ELN 2022 recommendations significantly expanded the role of new gene mutations. However, the impact of rare co-mutational patterns remains to be fully disclosed, and large international consortia such as the HARMONY project will hopefully be instrumental to this aim. Moreover, accumulating evidence suggests that clonal architecture plays a significant prognostic role. The integration of clinical, cytogenetic, and molecular factors is essential, but hierarchical methods are reaching their limit. Thus, innovative approaches are being extensively explored, including those based on “knowledge banks”. Indeed, more robust prognostic estimations can be obtained by matching each patient’s genomic and clinical data with the ones derived from very large cohorts, but further improvements are needed.

show abstract

Section: Emerging Biological Risk Factorsmentioning

confidence: 99%

Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors

Boscaro¹,

Urbino²,

Catania³

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022

Kaykı-Mutlu

Aksoyalp

Wojnowski

et al. 2023

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

While new drug approvals by the U.S. Food and Drug Administration (FDA) had remained stable or even increased in the first 2 years of the COVID-19 pandemic, the 37 newly approved drugs in 2022 are considerably less than the 53 and 50 new drugs approved in 2020 and 2021, respectively, and less than the rolling 10-year average of 43. As in previous years of this annual review, we assign these new drugs to one of three levels of innovation: first drug against a condition (“first-in-indication”), first drug using a novel molecular mechanism (“first-in-class”), and “next-in-class,” i.e., a drug using an already exploited molecular mechanism. We identify two “first-in-indication” (ganaxolon and teplizumab), 20 (54%) “first-in-class,” and 17 (46%) “next-in-class” drugs. By treatment area, rare diseases and cancer drugs were once again the most prevalent (partly overlapping) therapeutic areas. Other continuing trends were the use of accelerated regulatory approval pathways and the reliance on biopharmaceuticals (biologics).

show abstract

Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them

Li,

Chen,

Huang

et al. 2023

Expert Review of Hematology

View full text Add to dashboard Cite

LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study

Cited by 4 publications

References 50 publications

Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors

Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022

Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them

Contact Info

Product

Resources

About